Welcome & Introductions 
John Gribben & David Maloney

Session I:  CAR-T in AML
Chairs: Saar Gill & John DiPersio

• Clinical update on CART cell therapy for AML: Saar Gill
• Role of CART cells in the treatment of pediatric AML: Richard Aplenc
• CART or BITE in AML?: Marion Subklewe
• NK cells and CAR NK cells for AML: Rizwan Romee

Panel Discussion

 

Session 2: CAR-T in ALL
Chairs: Noelle Frey & Bijal Shah

• Allogeneic CARTs for ALL: Reuben Benjamin
• Factors associated with durable remissions after CART: Cameron Turtle
• Adult ALL and CART19: Claire Roddie
• Approaches to Dual Targeting with CARTs: Nirali Shah
• Updates on Neurotoxicity: Bianca Santomasso
• Bridging therapy and role of HSCT after CART: Jae Park

Panel Discussion

 

Session 3: CAR-T in CLL
Chairs: John Gribben & David Porter

• Combining ibrutinib with CD19 CAR T cells for CLL: Jordan Gauthier
• Transcend/JCAR – liso-cel: Tanya Siddiqi
• CAR NK treatments in CLL: Loretta Nastoupil
• CAR T Cells for CLL: When can we use the word “cure”?: David Porter

Panel Discussion

Day 1, Conclusions & Wrap up

 

 

Welcome & Introductions 
John Gribben & David Maloney

Session 4:  CAR-T in Myeloma
Chairs: Yi Lin & Noopur Raje

• BCMA CAR-Ts – Ide-cel/bb2121: Nina Shah
• Ciltacabtagene Autoleucel (Cilta-cel) – CARTITUDE: Saad Usmani
• Allo-CART: Sham Mailankody
• TCE – BCMA and non-BCMA targets: Adam Cohen
• CART in myeloma in China: Wang Jianxiang
• BITes vs CARs: Maria V Mateos

Panel Discussion

 

Session 5: Evolution of cellular therapies
Chairs: David Maloney & Yi Lin

• Epigenetics of CAR T cells: Michel Sadelain
• Logic-gated cell therapy: William Go
• Using CRISPR to enhance Immune cellular function: Eric Shifrut
• Innovative CAR designs: Renier Bretjens

Panel Discussion

Day 2, Conclusions & Wrap up

 

 

Welcome & Introductions
John Gribben & David Maloney

Session 7: Where are we with emerging CARs in solid tumors?
Chairs: Stan Riddell & Jennifer Specht

• alloSHRINK – Non-gene Edited Allogeneic CAR-T in mCRC: Sebastien Anguille
• CAR-T cells in MCRPC: Vivek Narayan
• ROR-1 in breast and lung cancer: Jennifer Specht
• CAR T-cell Therapy in Glioblastoma: Christine Brown

Panel discussion

• Signalling in solid tumors: Stan Riddell
• Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4: David Hong
• Auto TILs Lifileucel (LN-144) for Metastatic Melanoma: Amod Sarnaik
• Cell therapy trial updates in lung cancer and mesothelioma: Melissa Johnson

Panel Discussion

 

Session 8: Lymphoma
Chairs: Fred Locke and Caron Jacobson

• Axi-cel: Caron Jacobson
• Tisagenlecleucel in DLBCL: Stephen Schuster
• Liso-cel in DLBCL: Jeremy Abramson
• Updates in MCL: Fred Locke
• Dual CAR Targeting: David Miklos
• Third Generation CD20 Targeted CAR T-Cell Therapy: Mayzar Shadman
• A New Era of Targeted Therapy: Sonali Smith

Panel Discussion

Day 3, Conclusions & Wrap up